TYME Tyme Technologies, Inc. Stock Quote

TYME [NASD]

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	25.20%	Shs Outstand	172.21M	Perf Week	-2.08%
Market Cap	52.44M	Forward P/E	-	EPS next Y	-	Insider Trans	-4.96%	Shs Float	118.99M	Perf Month	9.23%
Income	-23.60M	PEG	-	EPS next Q	-	Inst Own	8.60%	Short Float	1.08%	Perf Quarter	-23.05%
Sales	-	P/S	-	EPS this Y	36.40%	Inst Trans	-5.66%	Short Ratio	1.93	Perf Half Y	-60.03%
Book/sh	0.47	P/B	0.56	EPS next Y	-	ROA	-24.70%	Target Price	-	Perf Year	-80.02%
Cash/sh	0.37	P/C	0.71	EPS next 5Y	-	ROE	-26.60%	52W Range	0.22 - 2.02	Perf YTD	-56.26%
Dividend	-	P/FCF	-	EPS past 5Y	5.30%	ROI	-	52W High	-86.94%	Beta	0.94
Dividend %	-	Quick Ratio	10.70	Sales past 5Y	-	Gross Margin	-	52W Low	20.62%	ATR	0.03
Employees	13	Current Ratio	10.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	49.02	Volatility	13.90% 11.32%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	15.00%	Profit Margin	-	Rel Volume	0.58	Prev Close	0.28
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	664.23K	Price	0.26
Recom	2.00	SMA20	0.44%	SMA50	-6.11%	SMA200	-53.11%	Volume	384,576	Change	-7.41%

May-25-22 07:15AM	TYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating Results GlobeNewswire
May-23-22 08:28AM	Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation Simply Wall St.
Mar-29-22 11:37AM	TYME Technologies Reviews Potential Strategic Options Benzinga +5.02%
07:01AM	Tyme Technologies shares jump premarket on news board to explore strategic options MarketWatch
06:50AM	TYME Technologies, Inc. Announces Exploration of Strategic Options GlobeNewswire
Mar-25-22 08:00AM	TYME Technologies, Inc. Announces Changes to its Board of Directors Business Wire +5.77%
Mar-09-22 06:50AM	TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022 GlobeNewswire +5.73%
Feb-11-22 06:50AM	TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results Business Wire
Jan-27-22 04:30PM	TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET Business Wire +8.81%
Jan-26-22 06:50AM	TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer Business Wire -37.46%
Jan-03-22 04:05PM	TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference Business Wire +7.79%
Dec-14-21 12:05PM	We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth Simply Wall St.
06:50AM	TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections Business Wire
Dec-09-21 06:50AM	TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Business Wire
Nov-08-21 06:50AM	TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results Business Wire
Nov-02-21 05:30PM	TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference Business Wire
Oct-27-21 04:30PM	TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET Business Wire
Sep-27-21 06:50AM	TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor Business Wire +5.56%
Sep-13-21 02:26PM	Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares? Simply Wall St.
Sep-02-21 06:50AM	TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences Business Wire
Aug-10-21 06:45AM	TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results Business Wire
Aug-02-21 04:05PM	TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET Business Wire
Jul-26-21 10:55AM	What You Need To Know Before Buying TYME Technologies Inc (NASDAQ: TYME) Stock Benzinga +27.78%
10:34AM	Tyme Technologies Skyrockets on Patent Claim Approval TheStreet.com
08:05AM	Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer Business Wire
Jun-21-21 06:50PM	Here is What Hedge Funds Think About Tyme Technologies, Inc. (TYME) Insider Monkey
Jun-14-21 09:24AM	Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation Simply Wall St.
Jun-10-21 04:17PM	Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results Business Wire
May-26-21 08:05AM	TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET Business Wire +6.77%
May-13-21 09:05AM	TYME Appoints Frank L. Porfido as Chief Financial Officer Business Wire
May-10-21 09:05AM	TYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual Meeting Business Wire -8.14%
Apr-01-21 08:00AM	TYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical Officer Business Wire +5.06%
Mar-15-21 10:38AM	Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders? Simply Wall St. +11.27%
Feb-09-21 12:00PM	Why Tyme Technologies Stock Is Taking Off Today Motley Fool +23.95%
Feb-08-21 12:46PM	TYME Announces Closing of $100 Million Registered Direct Offering of Common Stock Business Wire +10.50%
Feb-04-21 02:00PM	Why Tyme Stock Got Demolished Today Motley Fool -35.98%
08:00AM	TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results Business Wire
07:21AM	The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga
07:15AM	Why viral stocks are here to stay Yahoo Finance
01:22AM	TYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Business Wire
Feb-03-21 12:30PM	Why Tyme Technologies Stock Is Crushing It Today Motley Fool +93.96%
08:00AM	TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections Business Wire
Jan-08-21 04:02PM	SemiLEDs Reports First Quarter Fiscal Year 2021 Financial Results Business Wire
Jan-06-21 04:01PM	SemiLEDs to Announce Fiscal First Quarter 2021 Financial Results on Friday, January 8, 2021 Business Wire +5.80%
Dec-23-20 11:33AM	Insider Sells Tyme Technologies Shares Benzinga
Dec-15-20 03:47AM	We're Keeping An Eye On Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate Simply Wall St.
Dec-09-20 08:00AM	TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium Business Wire
Nov-30-20 08:00AM	TYME Builds Leadership Team with Announcement of New CEO Business Wire
Nov-27-20 11:00AM	Is Tyme Technologies, Inc. (TYME) Going to Burn These Hedge Funds? Insider Monkey
Nov-12-20 08:00AM	TYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating Results Business Wire
Oct-13-20 08:00AM	Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020 Business Wire
Sep-16-20 02:05PM	Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Sep-15-20 08:00AM	TYMEs Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs Business Wire
Sep-14-20 08:00AM	Tyme Technologies to Present at BioNJs 10th Annual BioPartnering Conference on October 6, 2020 Business Wire +6.26%
Sep-09-20 08:00AM	Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020 Business Wire
Sep-02-20 08:00AM	Tyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020 Business Wire +5.56%
Aug-26-20 08:00AM	TYMEs Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19 Business Wire
Aug-21-20 08:00AM	Tyme Technologies to Present at the 2020 CHINABIO® Partnering Forum Business Wire
Aug-19-20 08:00AM	TYME Announces Appointment of John Rothman, Ph.D. to Executive Vice President, Product Development Business Wire
Aug-18-20 11:43AM	Insider Sells Tyme Technologies's Shares Benzinga
Aug-11-20 08:00AM	TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study Business Wire
Aug-03-20 11:05AM	Why Tyme Technologies's Stock Is Trading Higher Today Benzinga +13.45%
08:00AM	TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer Business Wire
Jul-21-20 08:00AM	Tyme Technologies to Present at Canaccord 40th Annual Growth Conference on August 13, 2020 Business Wire
Jul-14-20 10:38AM	Insider Sells Tyme Technologies' Stock Benzinga +5.88%
Jul-13-20 05:00PM	TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results Business Wire
Jul-10-20 08:00AM	Tyme Technologies Announces Virtual 2020 Annual Meeting of Stockholders Business Wire
Jul-07-20 10:42AM	Insider Sells Tyme Technologies Shares Benzinga -5.26%
Jun-23-20 08:00AM	TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020 Business Wire -6.54%
Jun-22-20 08:00AM	TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 Business Wire +12.92%
Jun-04-20 05:10PM	Hedge Funds Are Nibbling On Tyme Technologies, Inc. (TYME) Insider Monkey
May-28-20 08:00AM	TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting Business Wire
May-27-20 08:00AM	Tyme Technologies to Present at BIO Digital from June 8-12, 2020 Business Wire
May-20-20 04:05PM	TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Business Wire
03:00PM	Tyme Technologies, Inc. to Host Earnings Call ACCESSWIRE
May-19-20 08:00AM	Tyme Technologies to Present at Jefferies Virtual Healthcare Conference on June 3, 2020 Business Wire
May-15-20 08:00AM	TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020 Business Wire +7.14%
May-12-20 08:00AM	Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020 Business Wire
May-06-20 10:41AM	How Tyme Technologies, Inc. (NASDAQ:TYME) Can Impact Your Portfolio Volatility Simply Wall St.
Apr-06-20 08:30AM	Tyme Technologies to Present at the 2020 Cross-Border Healthcare Webinar Series Business Wire +10.18%
Feb-05-20 08:00AM	TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Jan-27-20 08:00AM	Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care GlobeNewswire
Jan-16-20 08:00AM	TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas GlobeNewswire +12.07%
Jan-09-20 08:40AM	Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
Jan-08-20 10:18AM	Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:00AM	TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer GlobeNewswire
Jan-07-20 09:25AM	Tyme stock rises on Eage collaboration for cancer drug MarketWatch +13.64%
07:20AM	Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Dec-30-19 11:17AM	Analysts: These 3 Strong Buy Penny Stocks Could Soar in 2020 TipRanks +13.33%
Dec-23-19 02:55PM	Hedge Funds Have Never Been More Bullish On Tyme Technologies, Inc. (TYME) Insider Monkey
Dec-12-19 02:14PM	Wall Street Suggests These Falling Knives GuruFocus.com
Dec-04-19 08:00AM	Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York GlobeNewswire
Nov-25-19 08:00AM	TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer GlobeNewswire
Nov-21-19 08:00AM	Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019 GlobeNewswire +15.24%
Nov-07-19 08:00AM	Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019 GlobeNewswire
Nov-04-19 04:05PM	TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results GlobeNewswire
Oct-17-19 04:05PM	TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results GlobeNewswire
11:24AM	Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks
Oct-03-19 01:36PM	How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table? Simply Wall St.
Oct-01-19 08:00AM	TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer GlobeNewswire +6.30%

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Demurjian Michael	10% Owner	Jun 28	Sale	0.27	60,000	16,074	23,048,846	Jun 28 05:08 PM
Demurjian Michael	10% Owner	Jun 27	Sale	0.26	60,000	15,732	23,108,846	Jun 27 05:23 PM
Hoffman Steve	Director	Jun 22	Sale	0.27	78,125	21,094	20,022,566	Jun 23 04:05 PM
Hoffman Steve	Director	Jun 21	Sale	0.26	78,125	20,312	20,100,691	Jun 23 04:05 PM
Demurjian Michael	10% Owner	Jun 15	Sale	0.26	60,000	15,720	23,168,846	Jun 15 04:39 PM
Demurjian Michael	10% Owner	Jun 14	Sale	0.25	60,000	15,054	23,228,846	Jun 15 04:39 PM
Hoffman Steve	Director	Jun 09	Sale	0.27	78,125	21,094	20,178,816	Jun 10 06:33 PM
Hoffman Steve	Director	Jun 08	Sale	0.27	78,125	21,094	20,256,941	Jun 10 06:33 PM
Demurjian Michael	10% Owner	Jun 01	Sale	0.25	66,903	16,799	23,288,846	Jun 02 08:56 AM
Demurjian Michael	10% Owner	May 31	Sale	0.25	53,097	13,306	23,355,749	Jun 02 08:56 AM
Hoffman Steve	Director	May 26	Sale	0.24	78,125	18,750	20,335,066	May 27 04:05 PM
Hoffman Steve	Director	May 25	Sale	0.24	78,125	18,750	20,413,191	May 27 04:05 PM
Demurjian Michael	10% Owner	May 17	Sale	0.25	50,000	12,540	23,408,846	May 17 05:34 PM
Demurjian Michael	10% Owner	May 16	Sale	0.25	50,000	12,505	23,458,846	May 17 08:44 AM
Hoffman Steve	Director	May 10	Sale	0.28	78,125	21,875	20,491,316	May 11 04:05 PM
Hoffman Steve	Director	May 09	Sale	0.31	78,125	24,219	20,569,441	May 11 04:05 PM
Demurjian Michael	10% Owner	May 03	Sale	0.32	50,000	16,170	23,508,846	May 03 05:42 PM
Demurjian Michael	10% Owner	May 02	Sale	0.31	50,000	15,695	23,558,846	May 03 05:42 PM
Hoffman Steve	Director	Apr 28	Sale	0.32	78,125	25,000	20,647,566	Apr 29 04:07 PM
Hoffman Steve	Director	Apr 27	Sale	0.32	78,125	25,000	20,725,691	Apr 29 04:07 PM
Demurjian Michael	10% Owner	Apr 20	Sale	0.32	40,000	12,952	23,608,846	Apr 21 04:12 PM
Demurjian Michael	10% Owner	Apr 19	Sale	0.32	40,000	12,940	23,648,846	Apr 21 04:12 PM
Demurjian Michael	10% Owner	Apr 12	Sale	0.34	20,000	6,700	23,688,846	Apr 13 05:42 PM
Hoffman Steve	Director	Apr 12	Sale	0.32	78,125	25,000	20,803,816	Apr 13 04:05 PM
Hoffman Steve	Director	Apr 11	Sale	0.31	78,125	24,219	20,881,941	Apr 13 04:05 PM
Demurjian Michael	10% Owner	Apr 04	Sale	0.35	20,000	7,004	23,708,846	Apr 04 05:47 PM
Hoffman Steve	Chief Science Officer	Mar 29	Sale	0.36	78,125	27,805	20,960,066	Mar 30 04:05 PM
Demurjian Michael	10% Owner	Mar 28	Sale	0.34	20,000	6,900	23,728,846	Mar 29 04:58 PM
Hoffman Steve	Chief Science Officer	Mar 28	Sale	0.34	78,125	26,773	21,038,191	Mar 30 04:05 PM
Demurjian Michael	10% Owner	Mar 21	Sale	0.33	20,000	6,580	23,748,846	Mar 21 05:49 PM
Demurjian Michael	10% Owner	Mar 14	Sale	0.30	20,000	5,924	23,768,846	Mar 14 04:22 PM
Hoffman Steve	Chief Science Officer	Mar 11	Sale	0.31	78,125	24,219	21,116,316	Mar 14 04:05 PM
Hoffman Steve	Chief Science Officer	Mar 10	Sale	0.31	78,125	24,219	21,194,441	Mar 14 04:05 PM
Demurjian Michael	10% Owner	Mar 07	Sale	0.29	20,000	5,840	23,788,846	Mar 08 04:28 PM
Demurjian Michael	10% Owner	Feb 22	Sale	0.32	20,000	6,464	23,828,846	Feb 23 04:06 PM
Van Tornout Jan M	Acting Chief Medical Officer	Feb 17	Buy	0.36	7,022	2,528	9,831	Feb 22 04:05 PM
Biehl James	Chief Legal Officer	Feb 15	Buy	0.34	20,000	6,800	105,000	Feb 16 04:05 PM
Demurjian Michael	10% Owner	Feb 14	Sale	0.33	20,000	6,530	23,848,846	Feb 14 04:36 PM
Hoffman Steve	Chief Science Officer	Feb 08	Sale	0.36	78,125	28,125	21,428,816	Feb 09 04:05 PM
Demurjian Michael	10% Owner	Feb 07	Sale	0.36	20,000	7,124	23,868,846	Feb 08 04:10 PM
Hoffman Steve	Chief Science Officer	Feb 07	Sale	0.36	78,125	28,125	21,506,941	Feb 09 04:05 PM
Demurjian Michael	10% Owner	Jan 31	Sale	0.34	20,000	6,714	23,888,846	Jan 31 06:18 PM
Hoffman Steve	Chief Science Officer	Jan 26	Sale	0.34	78,125	26,563	21,585,066	Jan 27 04:05 PM
Hoffman Steve	Chief Science Officer	Jan 25	Sale	0.51	78,125	39,844	21,663,191	Jan 27 04:05 PM
Demurjian Michael	10% Owner	Jan 24	Sale	0.52	20,000	10,400	23,908,846	Jan 25 05:57 PM
Demurjian Michael	10% Owner	Jan 20	Sale	0.59	320	189	23,928,846	Jan 21 05:20 PM
Demurjian Michael	10% Owner	Jan 10	Sale	0.60	20,000	11,942	23,929,166	Jan 10 04:18 PM
Hoffman Steve	Chief Science Officer	Jan 06	Sale	0.62	78,125	48,438	21,741,316	Jan 07 04:15 PM
Hoffman Steve	Chief Science Officer	Jan 05	Sale	0.66	78,125	51,562	21,819,441	Jan 07 04:15 PM
Demurjian Michael	10% Owner	Jan 03	Sale	0.64	20,000	12,724	23,949,166	Jan 03 04:50 PM
Demurjian Michael	10% Owner	Dec 27	Sale	0.66	20,000	13,284	23,969,166	Dec 29 09:10 AM
Biehl James	Chief Legal Officer	Dec 23	Buy	0.65	10,000	6,500	85,000	Dec 27 04:05 PM
Demurjian Michael	10% Owner	Dec 21	Sale	0.70	20,000	14,020	23,989,166	Dec 21 04:58 PM
Hoffman Steve	Chief Science Officer	Dec 17	Sale	0.70	78,125	54,688	21,897,566	Dec 20 04:53 PM
Hoffman Steve	Chief Science Officer	Dec 16	Sale	0.72	78,125	56,250	21,975,691	Dec 20 04:53 PM
Demurjian Michael	10% Owner	Dec 13	Sale	0.75	20,000	14,912	24,009,166	Dec 14 04:06 PM
Demurjian Michael	10% Owner	Dec 07	Sale	0.73	20,000	14,690	24,029,166	Dec 08 07:37 AM
Hoffman Steve	Chief Science Officer	Dec 03	Sale	0.72	78,125	56,250	22,053,816	Dec 06 04:05 PM
Hoffman Steve	Chief Science Officer	Dec 02	Sale	0.72	78,125	56,250	22,131,941	Dec 06 04:05 PM
Demurjian Michael	10% Owner	Dec 02	Sale	0.75	20,000	14,962	24,049,166	Dec 06 08:11 AM
Hoffman Steve	Chief Science Officer	Nov 30	Sale	0.72	78,125	56,250	22,210,066	Dec 01 09:58 PM
Hoffman Steve	Chief Science Officer	Nov 29	Sale	0.74	78,125	57,812	22,288,191	Dec 01 09:58 PM
Demurjian Michael	10% Owner	Nov 22	Sale	0.80	9,380	7,531	24,069,166	Nov 29 05:56 PM
Demurjian Michael	10% Owner	Nov 17	Sale	0.91	20,000	18,258	24,078,546	Nov 18 04:45 PM
Hoffman Steve	Chief Science Officer	Nov 16	Sale	0.92	78,125	71,875	22,366,316	Nov 17 04:05 PM
Hoffman Steve	Chief Science Officer	Nov 15	Sale	0.92	78,125	71,875	22,444,441	Nov 17 04:05 PM
Galaini Barbara	See Remarks	Nov 12	Buy	0.95	10,000	9,500	20,000	Nov 15 04:51 PM
Biehl James	Chief Legal Officer	Nov 12	Buy	0.95	10,000	9,500	75,000	Nov 15 04:49 PM
PORFIDO FRANK L.	Chief Financial Officer	Nov 12	Buy	0.93	10,000	9,300	10,000	Nov 15 04:48 PM
Demurjian Michael	10% Owner	Nov 08	Sale	1.00	20,000	20,000	24,098,546	Nov 08 05:24 PM
Demurjian Michael	10% Owner	Nov 03	Sale	1.00	20,000	20,036	24,118,546	Nov 05 05:19 PM
Demurjian Michael	10% Owner	Oct 29	Sale	0.95	20,000	19,098	24,138,546	Oct 29 04:44 PM
Hoffman Steve	Chief Science Officer	Oct 27	Sale	0.96	78,125	75,000	22,522,566	Oct 28 05:00 PM
Hoffman Steve	Chief Science Officer	Oct 26	Sale	0.97	78,125	75,781	22,600,691	Oct 28 05:00 PM
Demurjian Michael	10% Owner	Oct 20	Sale	0.97	20,000	19,346	24,158,546	Oct 22 05:08 PM
Demurjian Michael	10% Owner	Oct 13	Sale	1.00	20,000	20,000	24,178,546	Oct 14 05:24 PM
Hoffman Steve	Chief Science Officer	Oct 05	Sale	1.00	78,125	78,125	22,678,816	Oct 06 04:05 PM
Demurjian Michael	10% Owner	Oct 04	Sale	1.00	20,000	20,022	24,198,546	Oct 04 04:53 PM
Hoffman Steve	Chief Science Officer	Oct 04	Sale	1.00	78,125	78,125	22,756,941	Oct 06 04:05 PM
Demurjian Michael	10% Owner	Sep 27	Sale	1.12	20,000	22,400	24,218,546	Sep 28 04:13 PM
Carberry David	Director	Sep 22	Buy	1.03	50,000	51,500	100,000	Sep 23 04:05 PM
Carberry David	Director	Sep 22	Buy	1.03	50,000	51,500	100,000	Sep 23 04:05 PM
Demurjian Michael	10% Owner	Sep 20	Sale	1.01	20,000	20,200	24,238,546	Sep 21 04:08 PM
Hoffman Steve	Chief Science Officer	Sep 15	Sale	1.03	172,850	178,036	22,835,066	Sep 17 04:09 PM
Demurjian Michael	10% Owner	Sep 13	Sale	1.04	20,000	20,800	24,258,546	Sep 13 05:42 PM
Demurjian Michael	10% Owner	Sep 07	Sale	1.12	20,000	22,400	24,278,546	Sep 07 05:08 PM
Hoffman Steve	Chief Science Officer	Sep 02	Sale	1.15	170,957	196,601	23,007,916	Sep 03 04:05 PM
Hoffman Steve	Chief Science Officer	Sep 01	Sale	1.13	78,525	88,733	23,178,873	Sep 03 04:05 PM
Demurjian Michael	10% Owner	Aug 30	Sale	1.10	20,000	22,000	24,298,546	Sep 01 08:42 AM
Hoffman Steve	Chief Science Officer	Aug 26	Sale	1.08	78,125	84,375	23,257,398	Aug 27 04:05 PM
Hoffman Steve	Chief Science Officer	Aug 25	Sale	1.08	78,125	84,375	23,335,523	Aug 27 04:05 PM
Demurjian Michael	10% Owner	Aug 23	Sale	1.03	20,000	20,600	24,318,546	Aug 24 07:55 AM
Demurjian Michael	10% Owner	Aug 16	Sale	1.02	20,000	20,466	24,338,546	Aug 17 06:26 PM
Van Tornout Jan M	Acting Chief Medical Officer	Aug 12	Buy	1.05	1,000	1,050	2,809	Aug 16 04:05 PM
Demurjian Michael	10% Owner	Aug 09	Sale	1.15	20,000	23,004	24,358,546	Aug 10 04:13 PM
Hoffman Steve	Chief Science Officer	Aug 04	Sale	1.07	84,225	90,121	23,413,648	Aug 05 04:07 PM
Hoffman Steve	Chief Science Officer	Aug 03	Sale	1.13	94,425	106,700	23,497,873	Aug 05 04:07 PM
Demurjian Michael	10% Owner	Aug 02	Sale	1.15	20,000	23,008	24,378,546	Aug 03 05:02 PM
Hoffman Steve	Chief Science Officer	Jul 30	Sale	1.15	87,925	101,114	23,592,298	Aug 02 04:05 PM
Hoffman Steve	Chief Science Officer	Jul 29	Sale	1.20	156,275	187,530	23,680,223	Aug 02 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience